JNJ-26854165 is a new drug in development and belongs to a class of drugs that act on the specific protein present in cells. It may stop cancer cells from growing or kill cancer cells. In this study, the safety (the effect on the body) of the JNJ-26854165 in patients with advanced or refractory solid tumors will be examined. The effect (if any) of JNJ-26854165 on the disease will be assessed throughout the study. The maximum dose tolerated by these patients will be determined.